Squarepoint
RCUS icon

Squarepoint’s Arcus Biosciences RCUS Stock Holding History

Squarepoint’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$772K Buy
29,877
+14,726
+97% +$415K ﹤0.01% 3003
2026
Q2 		$467K Sell
15,151
-51,523
-77% -$1.27M ﹤0.01% 3480
2026
Q1 		$1.44M Buy
+66,674
New +$1.44M ﹤0.01% 2450
2025
Q3 		– Sell
-199,649
Closed -$1.63M – 4880
2025
Q2 		$1.63M Buy
199,649
+123,938
+164% +$1.06M ﹤0.01% 2254
2025
Q1 		$594K Buy
+75,711
New +$878K ﹤0.01% 3137
2024
Q3 		– Sell
-16,700
Closed -$254K – 4595
2024
Q2 		$254K Buy
+16,700
New +$270K ﹤0.01% 3519
2024
Q1 		– Sell
-32,569
Closed -$622K – 4503
2023
Q4 		$622K Sell
32,569
-214,211
-87% -$3.42M ﹤0.01% 2858
2023
Q3 		$4.43M Sell
246,780
-27,668
-10% -$556K 0.01% 1253
2023
Q2 		$5.57M Buy
274,448
+186,862
+213% +$3.56M 0.02% 1016
2023
Q1 		$1.6M Buy
87,586
+53,961
+160% +$1.03M 0.01% 1572
2022
Q4 		$695K Buy
33,625
+17,527
+109% +$482K ﹤0.01% 2076
2022
Q3 		$421K Sell
16,098
-88,417
-85% -$2.34M ﹤0.01% 2284
2022
Q2 		$2.65M Buy
104,515
+2,819
+3% +$69K 0.01% 1024
2022
Q1 		$3.21M Buy
101,696
+84,281
+484% +$2.82M 0.01% 892
2021
Q4 		$705K Buy
+17,415
New +$676K ﹤0.01% 1922
2021
Q2 		– Sell
-30,473
Closed -$856K – 3614
2021
Q1 		$856K Sell
30,473
-52,975
-63% -$1.84M 0.01% 1633
2020
Q4 		$2.17M Sell
83,448
-31,715
-28% -$768K 0.02% 897
2020
Q3 		$1.97M Sell
115,163
-44,636
-28% -$997K 0.03% 653
2020
Q2 		$3.95M Buy
+159,799
New +$4.31M 0.06% 408
2020
Q1 		– Sell
-23,911
Closed -$242K – 2391
2019
Q4 		$242K Buy
+23,911
New +$201K ﹤0.01% 2136

Other funds holding RCUS

Gilead Sciences
Gilead Sciences Foster City, California $1.46B AUM 71.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Squarepoint's RCUS Position: Q3 2026 in Review

Squarepoint increased its Arcus Biosciences (RCUS) stake by 97% in Q3 2026, buying an estimated $415K and bringing the position to 29,877 shares worth $772K. The position accounts for ﹤0.01% of the portfolio, ranked #3003.

Squarepoint first reported a position in RCUS in Q4 2019 and has held it in 20 quarters since. The position peaked at $5.57M in Q2 2023. 137 funds tracked by Wall St. Rank hold RCUS as of Q3 2026.

  • Squarepoint held 29,877 shares of Arcus Biosciences worth $772K as of Q3 2026.
  • Squarepoint bought 14,726 Arcus Biosciences shares in Q3 2026, an estimated $415K.
  • Arcus Biosciences made up ﹤0.01% of Squarepoint's portfolio in Q3 2026, its #3003 holding.
  • Squarepoint first reported a position in Arcus Biosciences in Q4 2019 and has held it in 20 quarters since.
  • Squarepoint's Arcus Biosciences position peaked at $5.57M in Q2 2023.
  • 137 funds tracked by Wall St. Rank held Arcus Biosciences as of Q3 2026.

Based on Squarepoint's 13F filing for Q3 2026, filed 9 Nov 2026.